-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dalmitamig in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalmitamig in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalmitamig in Head And Neck Squamous Cell...
-
Sector Analysis
NewBronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
Bronchiectasis Market Report Overview The Bronchiectasis market across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) was valued at $1.4 billion in 2023 and the market will grow at a CAGR of more than 3% from 2023 to 2033. The 7MM (China, Japan, the United Kingdom, Spain, Italy, Germany, France, and the US). The market growth is attributed to the launch of brensocatib and an increase in the number of diagnosed prevalent cases of bronchiectasis. Bronchiectasis Market...
-
Company Insights
Innovation and Patenting activity of Regeneron Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Regeneron Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
Rare Disease ​Pipeline Analysis ​Landscape, 2023
This report investigates the Rare Disease ​Pipeline Analysis ​Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
-
Product Insights
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The cSCC clinical trial report provides a comprehensive understanding of the Cutaneous Squamous Cell Carcinoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Allergen For Allergic Rhinitis in Allergic Rhinitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Allergen For Allergic Rhinitis in Allergic Rhinitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Allergen For Allergic Rhinitis in Allergic Rhinitis Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5381 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5381 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5381 in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5381 in Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5381 in Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5381 in Hypertension Drug Details: REGN5381 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nezastomig in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nezastomig in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nezastomig in Renal Cell Carcinoma Drug Details: Nezastomig (REGN-5678) is...